Figure 1
The overall survival rates for control and immunochemotherapy-treated DLBCL patients according to molecular and clinical factors. (A) OS according to immunohistochemically defined GC (n = 47) versus non-GC (n = 57) distinction for patients treated with chemotherapy. (B) OS according to immunohistochemically defined GC (n = 50) versus non-GC (n = 40) distinction for patients treated with immunochemotherapy. (C) OS according to IPI (0-2, n = 54 vs 3-5, n = 36) for patients treated with immunochemotherapy.

The overall survival rates for control and immunochemotherapy-treated DLBCL patients according to molecular and clinical factors. (A) OS according to immunohistochemically defined GC (n = 47) versus non-GC (n = 57) distinction for patients treated with chemotherapy. (B) OS according to immunohistochemically defined GC (n = 50) versus non-GC (n = 40) distinction for patients treated with immunochemotherapy. (C) OS according to IPI (0-2, n = 54 vs 3-5, n = 36) for patients treated with immunochemotherapy.

Close Modal

or Create an Account

Close Modal
Close Modal